Mereo BioPharma Group PLC - clinical stage biopharmaceutical company - Gains clearance for investigational new drug application from US Food & Drug Administration for a phase 1/2b study of lead oncology product candidate etigilimab.
Product is a monoclonal antibody against a T-cell immunoreceptor, a next generation checkpoint receptor shown to block T-cell activation and the body's natural anti-cancer immune response. Mereo on-track to initiate the basket study in the fourth quarter of 2020.
Current stock price: 37.84 pence
Year-to-date change: up 6.6%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.